Heart failure affects millions of people worldwide and can significantly impact quality of life. Research into new treatment approaches remains critical to improving outcomes and expanding options for patients living wit...
-
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials
ICON plc today announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON’s digital innovation and AI strategy, and builds on Orbis – ICON’s secure, governed, agentic AI platform.
-
ICON schedules second quarter 2026 earnings conference call
ICON will release its financial results for the second quarter 2026 after the market closes on Wednesday, July 29, 2026.
-
ICON reports first quarter 2026 results
Quarter one revenue of $2,034.0 million, an increase of 0.9% on quarter one 2025.
-
ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development
Advancing ICON’s previously announced plan to invest in digital innovation and AI over the next three years.
-
ICON schedules first quarter 2026 earnings conference call
ICON will release its financial results for the first quarter 2026 after the market closes on Tuesday, June 23, 2026.
-
ICON reports fourth quarter and full year 2025 results
ICON plc today reported its financial results for the fourth quarter and full year 2025, and announced the outcome of its investigation by the Audit Committee of the Board of Directors into certain accounting practices.
-
ICON expands US early phase research capabilities
ICON plc today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas.
-
ICON provides update on audit committee investigation and timing of fourth quarter and full year 2025 financial results
ICON plc today announced that the Audit Committee of the Board of Directors has completed its investigation into certain of the Company’s accounting practices and controls.
-
ICON and Advarra introduce new ‘research-ready,’ connected site network model
ICON plc and Advarra have entered a definitive partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials.
-
ICON plc provides update on timing of fourth quarter and full year 2025 earnings results and investigation into accounting practices
Investigation’s preliminary indications are that 2023 and 2024 revenue may have been overstated by less than 2% for each fiscal year
